Patients with kidney disease who take calcium-based phosphate binders to lower their phosphorus levels may be at a 22% higher risk of death that those who take other non-calcium based treatments.
A new study by Canadian researchers has found a reduction in the risk of death among patients who took the non-calcium based treatments sevelamer and lanthanum.
Continue Reading
John Schieszer has the story in today’s Medical Minute.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.